Provenge Should Be "Very Familiar" To CMS Now, Dendreon Says About NCA

Dendreon has already provided the Centers for Medicare and Medicaid Services with extensive information on its new prostate cancer vaccine Provenge (sipuleucel-T), so a lengthy Medicare national coverage analysis is not needed, the firm maintained in July 27 comments to the agency